Know Cancer

or
forgot password

An Observational Study of AvastinĀ® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma


N/A
18 Years
N/A
Open (Enrolling)
Both
Colorectal Cancer

Thank you

Trial Information

An Observational Study of AvastinĀ® (Bevacizumab) in Combination With Chemotherapy for Treatment of First-line Metastatic Colorectal Adenocarcinoma


Inclusion Criteria:



- Adult patients, >/= 18 years of age

- Metastatic colorectal cancer with no previous systemic treatment for advanced disease

- Receiving Avastin in combination with a first-line standard of care chemotherapy
regimen

- Avastin initiated at the same time as first-line chemotherapy regimen

Exclusion Criteria:

- Investigational, non-standard of care first-line chemotherapy regimen for treatment
of metastatic colorectal cancer

- Contraindication to Avastin

Type of Study:

Observational

Study Design:

Observational Model: Cohort, Time Perspective: Prospective

Outcome Measure:

Safety (incidence of serious adverse events)

Outcome Time Frame:

1.5 years

Safety Issue:

No

Principal Investigator

Clinical Trials

Investigator Role:

Study Director

Investigator Affiliation:

Hoffmann-La Roche

Authority:

United Kingdom: Medicines and Healthcare Products Regulatory Agency

Study ID:

ML27971

NCT ID:

NCT01506167

Start Date:

July 2012

Completion Date:

June 2016

Related Keywords:

  • Colorectal Cancer
  • Colorectal Neoplasms

Name

Location